Moleculin Biotech Inc
LSE:0K2H
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Moleculin Biotech Inc
LSE:0K2H
|
US |
|
M
|
Murphy Oil Corp
LSE:0K3S
|
US |
|
K
|
Kirloskar Brothers Ltd
BSE:500241
|
IN |
|
A
|
AUTO1 Group SE
XBER:AG1
|
DE |
Income Statement
Earnings Waterfall
Moleculin Biotech Inc
Income Statement
Moleculin Biotech Inc
| Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(4)
|
(5)
|
(6)
|
(7)
|
(9)
|
(10)
|
(14)
|
(14)
|
(15)
|
(17)
|
(15)
|
(17)
|
(18)
|
(18)
|
(19)
|
(21)
|
(20)
|
(21)
|
(21)
|
(21)
|
(23)
|
(24)
|
(26)
|
(29)
|
(31)
|
(32)
|
(31)
|
(28)
|
(30)
|
(28)
|
(28)
|
(29)
|
(27)
|
(26)
|
(25)
|
(24)
|
(25)
|
|
| Selling, General & Administrative |
(2)
|
(3)
|
(3)
|
(4)
|
(4)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(6)
|
(6)
|
(6)
|
(7)
|
(7)
|
(7)
|
(7)
|
(7)
|
(8)
|
(8)
|
(8)
|
(9)
|
(10)
|
(11)
|
(12)
|
(12)
|
(11)
|
(11)
|
(10)
|
(10)
|
(9)
|
(9)
|
(9)
|
(9)
|
(9)
|
(9)
|
(9)
|
|
| R&D |
(1)
|
(2)
|
(3)
|
(3)
|
(5)
|
(5)
|
(9)
|
(9)
|
(10)
|
(11)
|
(9)
|
(11)
|
(11)
|
(11)
|
(13)
|
(14)
|
(13)
|
(14)
|
(13)
|
(13)
|
(14)
|
(15)
|
(16)
|
(18)
|
(19)
|
(20)
|
(20)
|
(17)
|
(19)
|
(18)
|
(18)
|
(20)
|
(18)
|
(17)
|
(16)
|
(15)
|
(16)
|
|
| Depreciation & Amortization |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Operating Income |
(4)
N/A
|
(5)
-31%
|
(6)
-12%
|
(7)
-17%
|
(9)
-30%
|
(10)
-13%
|
(14)
-42%
|
(14)
-1%
|
(15)
-7%
|
(17)
-13%
|
(15)
+11%
|
(17)
-13%
|
(18)
-3%
|
(18)
-3%
|
(19)
-8%
|
(21)
-8%
|
(20)
+6%
|
(21)
-5%
|
(21)
-2%
|
(21)
0%
|
(23)
-8%
|
(24)
-4%
|
(26)
-8%
|
(29)
-11%
|
(31)
-6%
|
(32)
-4%
|
(31)
+3%
|
(28)
+10%
|
(30)
-7%
|
(28)
+4%
|
(28)
+1%
|
(29)
-2%
|
(27)
+8%
|
(26)
+3%
|
(25)
+2%
|
(24)
+5%
|
(25)
-4%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
(0)
|
1
|
(1)
|
(2)
|
(1)
|
(2)
|
1
|
2
|
3
|
3
|
5
|
5
|
4
|
7
|
(0)
|
3
|
2
|
0
|
7
|
6
|
7
|
6
|
5
|
4
|
2
|
2
|
2
|
1
|
0
|
2
|
3
|
3
|
1
|
2
|
0
|
0
|
0
|
|
| Non-Recurring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
0
|
0
|
(2)
|
0
|
(3)
|
(4)
|
(4)
|
(1)
|
|
| Total Other Income |
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
0
|
3
|
3
|
(14)
|
(7)
|
|
| Pre-Tax Income |
(4)
N/A
|
(4)
+0%
|
(7)
-68%
|
(8)
-22%
|
(10)
-22%
|
(11)
-16%
|
(13)
-15%
|
(12)
+6%
|
(12)
+3%
|
(14)
-18%
|
(10)
+28%
|
(12)
-23%
|
(13)
-8%
|
(11)
+21%
|
(19)
-84%
|
(19)
+5%
|
(17)
+6%
|
(21)
-19%
|
(15)
+28%
|
(16)
-7%
|
(16)
-1%
|
(18)
-15%
|
(21)
-14%
|
(25)
-20%
|
(29)
-16%
|
(30)
-4%
|
(29)
+3%
|
(26)
+10%
|
(30)
-13%
|
(27)
+10%
|
(25)
+6%
|
(30)
-20%
|
(26)
+14%
|
(23)
+11%
|
(27)
-14%
|
(41)
-56%
|
(34)
+19%
|
|
| Net Income | ||||||||||||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(4)
|
(4)
|
(7)
|
(8)
|
(10)
|
(11)
|
(13)
|
(12)
|
(12)
|
(14)
|
(10)
|
(12)
|
(13)
|
(10)
|
(19)
|
(19)
|
(17)
|
(21)
|
(15)
|
(16)
|
(16)
|
(18)
|
(21)
|
(25)
|
(29)
|
(30)
|
(29)
|
(26)
|
(30)
|
(27)
|
(25)
|
(30)
|
(26)
|
(23)
|
(27)
|
(41)
|
(34)
|
|
| Net Income |
(4)
N/A
|
(4)
+0%
|
(7)
-68%
|
(8)
-22%
|
(10)
-22%
|
(11)
-16%
|
(13)
-15%
|
(12)
+6%
|
(12)
+3%
|
(14)
-18%
|
(10)
+28%
|
(12)
-21%
|
(13)
-8%
|
(10)
+21%
|
(19)
-86%
|
(19)
+4%
|
(17)
+6%
|
(21)
-19%
|
(15)
+28%
|
(16)
-7%
|
(16)
-1%
|
(18)
-15%
|
(21)
-14%
|
(25)
-20%
|
(29)
-16%
|
(30)
-4%
|
(29)
+3%
|
(26)
+10%
|
(30)
-13%
|
(27)
+10%
|
(25)
+6%
|
(30)
-20%
|
(26)
+14%
|
(23)
+11%
|
(27)
-14%
|
(41)
-56%
|
(34)
+19%
|
|
| EPS (Diluted) |
-898.48
N/A
|
-605.41
+33%
|
-832.29
-37%
|
-880.86
-6%
|
-1 188.48
-35%
|
-1 099.51
+7%
|
-1 138.4
-4%
|
-1 028.05
+10%
|
-1 031.79
0%
|
-1 082.73
-5%
|
-535.29
+51%
|
-603.26
-13%
|
-729.55
-21%
|
-467.41
+36%
|
-728.55
-56%
|
-677.63
+7%
|
-660.89
+2%
|
-354.04
+46%
|
-194.05
+45%
|
-206.12
-6%
|
-221.76
-8%
|
-240.32
-8%
|
-273.48
-14%
|
-328.53
-20%
|
-380.5
-16%
|
-392.23
-3%
|
-369.73
+6%
|
-330.44
+11%
|
-376.72
-14%
|
-271.91
+28%
|
-247.39
+9%
|
-202.93
+18%
|
-189.14
+7%
|
-62.15
+67%
|
-42.74
+31%
|
-27.71
+35%
|
-28.42
-3%
|
|